ONKOLOGIE / Onkologie. 2023;17(2):90-94 / www.onkologiecs.cz 94 HLAVNÍ TÉMA Role radioterapie v léčbě nádorů pankreatu LITERATURA 1. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010. 2. Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776-782. 3. Neoptolemos JP, Stocken DD, Friess H, et al. Role of Radiation Therapy in Pancreas Cancer randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. 4. Regine W, Winter KA, Abrams R, et al. A phase III Intergroup trial (RTOG 97-04) of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys.20006;66:S23-S24. 5. Griffin J, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56-61. 6. Safran H, Winter K, Abrams RA, et al. Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. J Clin Oncol. 2017;35:4007. 7. Ren F, Xu YC, Wang HX, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology. 2012;12(2):162-169. 8. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14(11):1095-1103. 9. Luo Y. The role of radiotherapy for pancreatic malignancies: a population‑based analysis of the SEER database. Clinical and Translational Oncology. 2022;24:76-83. 10. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. 11. Ghaneh P, Kleeff J, Halloran ChM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520-529. 12. van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer. 2022;140-149. 13. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. JCO. 2020. 14. Suker M, Nuyttens JJ, Groot Koerkamp B, et al. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol. 2018;118:1021-1026. 15. Neoadjuvant FOLFIRINOX versus neoadjuvant chemoradiotherapy and adjuvant chemotherapy for (borderline) resectable pancreatic carcinoma: the PREOPANC-2 study. Available from: https://www. trialregister.nl/trial/7094. 16. Katz M, Shi Q, Meyers A, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263-1270. 17. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022. 18. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844-1853. 19. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic Cancer patients receiving induction chemotherapy and consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755-765. 20. Rudra S, Jiang N, Rosenberg A, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123-2132. 21. Reyngold M, Parikh P, Crane ChH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019;6:4(1):95. 22. Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313-322. 23. de Geus SWL, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123(21):4158-4167. 24. Iacobuzio-Donahue CA, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11): 1806-1813. 25. Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer. 2021;21:936. 26. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126:519-526. 27. Scorsetti M, Comito T, Franceschini D, et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Br J Radiol. 2020; 93:20190627. 28. Lee G, Kim DW, Oladeru OT, et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy: Data from a multi-institutional retrospective study. Pancreas. 2021;50:736-743. 29. Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516-524. 30. Venkatesulu BP, Cheng-En Hsieh, Sanders KL, et al. Recent advances in radiation therapy of pancreatic cancer. F1000Research 2018, 7(F1000 Faculty Rev):1931 Last updated:14 DEC 2018. 31. Palta M, Godfrey D, Goodman KA, et al. ASTRO Guideline Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology. 2019;9:322-332. 32. Nelson B, Barrord M, Wang K, et al. Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation. Front Oncol. 2022;12:906484. KNIŽNÍ NOVINKA Jan Bauer METASTAZUJÍCÍ KOLOREKTÁLNÍ KARCINOM Nová paradigmata, nové výzvy Cílem publikace je podat srozumitelný přehled o nových poznatcích v biologii, imunitě a diagnostice mCRC ve vztahu k existujícím a nově se objevujícím možnostem léčby. Stručně jsou vždy popsány mechanismy účinku léčiv, léčebné výsledky jsou obvykle uvedeny ve formě tabulek nebo grafů, přičemž zahrnuty jsou pouze výsledky z rozhodujících randomizovaných a/nebo kontrolovaných studií. Maxdorf 2022, 296 str., barevné ilustrace, edice Jessenius, ISBN: 978-80-7345-730-3, Cena: 595 Kč, Formát: 160×225mm, brožovaná Maxdorf, s. r. o., Na Šejdru 247/6a, 142 00 Praha 4, tel.: 241 011 681–9, fax: 241 710 245, www.maxdorf.cz, e-mail: info@maxdorf.cz
RkJQdWJsaXNoZXIy NDA4Mjc=